Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + cisplatin + vinorelbine
- Development stage
- Unknown
- Lead developer
- Gruppo Oncologico Campano
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A chemotherapy combination regimen consisting of two platinum-based agents (carboplatin and cisplatin) plus vinorelbine, a vinca alkaloid. This combination is primarily used in the treatment of advanced non-small-cell lung cancer (NSCLC). The regimen typically involves carboplatin administered at an area under the curve (AUC) of 7 on a monthly basis, cisplatin given at doses ranging from 30-40 mg/m², and vinorelbine administered at approximately 30 mg/m² weekly. Treatment cycles are usually repeated every 28-29 days.
02
Targets
MicrotubuleDNA
Beyond the preview
Go deeper on carboplatin + cisplatin + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + cisplatin + vinorelbine.